For instance, co-administration of rapamycin and cisplatin is effective in inducing p73-dependent cell death in breast cancer basal-like cells expressing mut-p53, representing a potential useful therapeutic strategy that is currently investigated in a clinical trial (NCT00930930) [156]. The gene discussed is TP73; the disease is breast cancer.